Clinical Trial Update: Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 study characterizing systemic exposure from topical [14C] umeclidinium applied to the axilla or palm in healthy male subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperhidrosis

Drugs mentioned

• Umeclidinium (umeclidinium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hyperhidrosis | Phase 1 | Status: COMPLETED